Payers and targeted therapy in oncology

I was quoted in a recent article in Pharmaceutical Technology titled “Targeted therapies to join chemo as oncology treatment backbone“. An excerpt is below: Though payers could theoretically prioritise chemotherapy over the use of targeted treatments due to their lower price, Jason Shafrin, senior managing director of FTI’s Center for Healthcare Economics and Policy, notes…

Read More

Chronic Overmedication: The Polypharmacy Waste and Safety Problem

Polypharmacy is a cost and safety problem that is solvable. The right technology platform can reduce it by identifying risky regimens, route specific “stop/switch/consolidate” opportunities to clinicians, and track whether changes stick through refill and adherence patterns. The post Chronic Overmedication: The Polypharmacy Waste and Safety Problem appeared first on MedCity News.

Read More